AstraZeneca Settles Two-Thirds of Seroquel Lawsuits
This article is for subscribers only.
AstraZeneca Plc will pay about $198 million to settle 17,500 lawsuits, or about two-thirds of the total cases alleging its antipsychotic drug Seroquel causes diabetes in some users.
The settlements resulted from court-ordered mediation, the London-based drugmaker said in a statement today. AstraZeneca previously agreed to pay at least $55 million to resolve more than 5,500 cases alleging the company knew Seroquel could cause diabetes and failed to adequately warn patients, people familiar with those settlements said. These earlier agreements are part of the 17,500 settlements, the company said.